AR-15512 is a differentiated, novel, first-in-class product candidate for the treatment of the signs and symptoms of Dry Eye Disease COMET-2 is the first of three studies in the AR-15512 Phase 3 Program DURHAM, N.C. --(BUSINESS WIRE)--May 24, 2022-- Aerie Pharmaceuticals, Inc.
First Quarter Glaucoma Franchise Net Revenues of $29.8 Million , up 30% over First Quarter 2021 Management Reaffirms 2022 Glaucoma Franchise Guidance of $130 Million to $140 Million First Phase 3 Registrational Trial for AR-15512 On-Track for Enrollment Second Quarter of 2022 DURHAM, N.C.
DURHAM, N.C. --(BUSINESS WIRE)--Apr. 28, 2022-- Aerie Pharmaceuticals, Inc. (NASDAQ: AERI), a pharmaceutical company focused on the discovery, development and commercialization of first-in-class ophthalmic therapies, today announced that it will present first quarter 2022 financial results after
Abstracts showcase Rhopressa ® / netarsudil, AR-15512 and “ROCK’Ster” DURHAM, N.C. --(BUSINESS WIRE)--Apr. 26, 2022-- Aerie Pharmaceuticals, Inc. (NASDAQ: AERI), a pharmaceutical company focused on the discovery, development and commercialization of first-in-class ophthalmic therapies, today
Data adds to real-world use and clinical research on netarsudil (Rhopressa ® ) DURHAM, N.C. --(BUSINESS WIRE)--Apr. 20, 2022-- Aerie Pharmaceuticals, Inc. (NASDAQ: AERI), a pharmaceutical company focused on the discovery, development and commercialization of first-in-class ophthalmic therapies,
DURHAM, N.C. --(BUSINESS WIRE)--Apr. 6, 2022-- Aerie Pharmaceuticals, Inc. (NASDAQ: AERI), a pharmaceutical company focused on the discovery, development and commercialization of first-in-class ophthalmic therapies, today announced that Raj Kannan , Chief Executive Officer, along with Peter Lang ,
Finance executive with a successful track record in capital creation, deployment, and optimization Brings breadth of finance, strategy and business development experience DURHAM, N.C. --(BUSINESS WIRE)--Mar. 18, 2022-- Aerie Pharmaceuticals, Inc. (NASDAQ: AERI), a pharmaceutical company focused on
2021 Glaucoma Franchise Net Revenues of $112.1 Million , an Increase of 35% over 2020 Fourth Quarter Glaucoma Franchise Net Revenues of $32.7 Million , up 11% From Third Quarter Guidance of $130 Million to $140 Million in 2022 Glaucoma Franchise Forecasted Net Revenues, up 16% to 25% DURHAM, N.C.
Fellowship-trained Ophthalmologist and well-rounded biopharmaceutical executive b rings breadth of clinical development, medical affairs, strategy, and business development experience DURHAM, N.C. --(BUSINESS WIRE)--Feb. 24, 2022-- Aerie Pharmaceuticals, Inc.
DURHAM, N.C. --(BUSINESS WIRE)--Feb. 17, 2022-- Aerie Pharmaceuticals, Inc. (NASDAQ: AERI), a pharmaceutical company focused on the discovery, development and commercialization of first-in-class ophthalmic therapies, today announced that its fourth quarter and full year 2021 financial results will
